science
Experimental Model Shows Diet Restricting Two Amino Acids May Target Aggressive Childhood Brain Cancer
Researchers have identified a potential treatment mechanism for diffuse intrinsic pontine glioma (DIPG), an aggressive brain cancer in children, through dietary restriction of two essential amino acids. The approach was tested in an experimental model, demonstrating reduced tumor growth.
ER
Hunted230 / Wikimedia (CC BY-SA 3.0)Audio version
Tap play to generate a narrated version.
Diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive form of brain cancer that primarily affects children. It originates in the pons, a region of the brainstem responsible for vital functions such as breathing and heart rate. The disease has a poor prognosis, with most cases diagnosed between ages 5 and 10, and limited effective treatments available.
A recent study explored the effects of dietary modification on DIPG using an experimental model. Researchers restricted two essential amino acids—methionine and cysteine—in the diet of the model subjects. This intervention targeted the tumor's metabolic dependencies, leading to slowed tumor progression.
The experimental model involved preclinical testing to examine the underlying mechanism. Results indicated that depriving the tumors of these amino acids disrupted their growth processes without broadly affecting healthy cells. @EricTopol reported on the study's findings, noting the establishment of a potential therapeutic pathway.
The mechanism involves the tumors' reliance on methionine and cysteine for protein synthesis and other cellular functions.
By eliminating these amino acids, the diet induced a metabolic stress that selectively impaired tumor cells. The study, published in a peer-reviewed journal, provided evidence from controlled experiments supporting this approach. DIPG affects approximately 200 to 300 children annually in the United States, with survival rates below 10% at two years post-diagnosis.
Current standard treatments include radiation therapy, which offers temporary symptom relief but does not cure the disease. The dietary strategy represents an adjunctive option that could complement existing therapies.
research is needed to translate these findings to human clinical trials.
Potential challenges include ensuring nutritional adequacy for growing children while implementing the restriction. Regulatory bodies such as the FDA would require safety and efficacy data before approving any such intervention. The study's authors emphasized the need for additional validation in larger models and early-phase trials.
